2. Search Result
Search Result
Results for "

Ipatasertib

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15186
    Ipatasertib
    Maximum Cited Publications
    39 Publications Verification

    GDC-0068; RG7440

    		 Organoid Akt Apoptosis Cancer
    Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
    Ipatasertib
  • HY-130988
    Ipatasertib-NH2

    GDC-0068-NH2; RG7440-NH2

    		 Ligands for Target Protein for PROTAC Cancer
    Ipatasertib-NH2 (GDC-0068-NH2;RG7440-NH2) is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase .
    Ipatasertib-NH2
  • HY-15186A
    Ipatasertib dihydrochloride
    Maximum Cited Publications
    39 Publications Verification

    GDC-0068 dihydrochloride; RG-7440 dihydrochloride

    		 Organoid Akt Cancer
    Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.
    Ipatasertib dihydrochloride
  • HY-133120
    INY-03-041

    		PROTACs Akt Cancer
    INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively .
    INY-03-041
  • HY-133120A
    INY-03-041 trihydrochloride

    		PROTACs Akt Cancer
    INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively .
    INY-03-041 trihydrochloride
  • HY-130988A
    Ipatasertib-NH2 dihydrochloride

    GDC-0068-NH2 dihydrochloride; RG7440-NH2 dihydrochloride

    		 Ligands for Target Protein for PROTAC Cancer
    Ipatasertib-NH2 dihydrochloride is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase .
    Ipatasertib-NH2 dihydrochloride
  • HY-15186C
    Ipatasertib tosylate

    GDC-0068 tosylate; RG7440 tosylate

    		 Akt Cancer
    Ipatasertib (GDC-0068) (tosylate) is a highly selective ATP-competitive pan-Akt inhibitor with antitumor effects. Ipatasertib (tosylate) prevents colon cancer growth through p53-independent p53 upregulated modulator of apoptosis (PUMA) dependent Apoptosis. Ipatasertib (tosylate) leads to PUMA activation by inhibiting Akt, thereby activating both FoxO3a and NF-κB synchronously that will directly bind to PUMA promoter, up-regulating PUMA transcription and Bax-mediated intrinsic mitochondrial Apoptosis .
    Ipatasertib tosylate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: